JOSEPH LANSDEN: Open Payments
NPI 1518526227 · HENDERSON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$863 in 44 payments from 16 companies in 2025. Trend: 2023 $747 · 2024 $728 · 2025 $863
Food & beverage: $863
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $194 |
| AstraZeneca Pharmaceuticals LP | 2 | $150 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| PFIZER INC. | 4 | $66 |
| Corium, LLC | 4 | $65 |
| Novo Nordisk Inc | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: FARXIGA, VRAYLAR, UBRELVY, ELIQUIS, Azstarys, GEMTESA, REXULTI, VOQUEZNA.
Industry payments across KY — which companies pay providers there.
